Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a single arm, open label study designed to evaluate the safety and efficacy of
propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis. Treatment will
be comprised of propylene glycol-free melphalan hydrochloride administered intravenously at a
dose of 70-100 mg/m2/day on Days -3 and -2 as conditioning prior to autologous stem cell
transplantation.